Gillies is CSO of Alopexx Oncology and Founder and CEO of Provenance Biopharmaceuticals corp. His current interests include clinical development of a novel immunotherapeutic agent for Non-Hodgkin's lymphoma and other B-cell cancers. Prior to founding Provenance, Dr Gillies led all scientific and business endeavours of Lexigen Pharmaceuticals Corp. After Lexigen was acquired in 1999 by Merck KGaA, Dr Gillies had responsibility for oversight Merck's Global Oncology pre-clinical research. He was previously Vice President of Research at Damon Biotech and Abbott Biotech Inc., where he oversaw development of recombinant antibodies and of pro-urokinase, an anti-clotting protein. Dr Gillies’ postdoctoral fellow research at MIT was a key part of the commercial success of Erbitux, a cancer drug marketed by Eli Lilly, Bristol Myers Squibb, and Merck KGaA. A second antibody created by Dr Gillies gained market approval in March 2015 for treatment paediatric neuroblastoma. As part of his recombinant antibody project work, Dr. Gillies invented and developed immunocytokine (antibody-cytokine fusion protein) technology and leveraged, through his academic network, the first clinical proof of concept of this approach. Gillies is CSO of Alopexx Oncology and Founder and CEO of Provenance Biopharmaceuticals corp. His current interests include clinical development of a novel immunotherapeutic agent for Non-Hodgkin's lymphoma and other B-cell cancers. Prior to founding Provenance, Dr Gillies led all scientific and business endeavours of Lexigen Pharmaceuticals Corp. After Lexigen was acquired in 1999 by Merck KGaA, Dr Gillies had responsibility for oversight Merck's Global Oncology pre-clinical research. He was previously Vice President of Research at Damon Biotech and Abbott Biotech Inc., where he oversaw development of recombinant antibodies and of pro-urokinase, an anti-clotting protein. Dr Gillies’ postdoctoral fellow research at MIT was a key part of the commercial success of Erbitux, a cancer drug marketed by Eli Lilly, Bristol Myers Squibb, and Merck KGaA. A second antibody created by Dr Gillies gained market approval in March 2015 for treatment paediatric neuroblastoma. As part of his recombinant antibody project work, Dr. Gillies invented and developed immunocytokine (antibody-cytokine fusion protein) technology and leveraged, through his academic network, the first clinical proof of concept of this approach.

fermentation